뉴스

• Cellid Crashes After-Hours on Phase 3 Failure...Shaperon Dives 25%[K-bio pulse] In the biopharmaceutical sector on Friday, Cellid’s stock surged on expectations for its vaccine clinical trial results, but the shares plunged by the dai www.edaily.co.kr · 2026.06.29